Meeting Coverage > > ASH Expert Roundtable: Follicular Lymphoma– Novel CD19xCD3 T-cell engager revealed high reaction rate in stage I research study
by Greg Laub, Director, Video, MedPage Today January 2, 2025
At the current American Society of Hematology (ASH) yearly conference, information from a stage I trial of AZD0486– an unique CD19xCD3 bispecific T-cell engager– revealed high reaction rates and motivating security in relapsed/refractory follicular lymphoma clients, highlighting its possible function in sequencing methods.
In this 3rd of 4 unique episodes, MedPage Today combined 3 professional leaders in the field, all from the Ohio State University Wexner Medical Center in Columbus. Mediator Kami Maddocks, MD, is signed up with by Yazeed Sawalha, MD, and David Bond, MD, for a conversation on the appealing early outcomes of AZD0486 and its developing function in follicular lymphoma treatment.
Following is a records of their remarks:
Maddocks: Welcome back to this ASH 2024 Roundtable, where I’m talking to Dr. Bond and Dr. Sawalha about brand-new information out of ASH in follicular lymphoma. Next, I ‘d like to talk about the abstract [about] intensifying dosages of AZD0486, an unique CD19xCD3 T-cell engager. Dr. Sawalha, would you like to supply us with some ideas on this abstract and sum up?
Sawalha: Yeah, so I believed that was really interesting information. This is a CD19 T-cell engager developed to bind with low affinity to CD3 T cells to possibly reduce the danger of CRS [cytokine release syndrome]and after that it targets CD19 on B cells comparable to the other CD19-directed treatments. It was offered IV [intravenously] with 2 step-up dosing schema to lower the threat of CRS and ICANS [immune effector cell-associated neurotoxicity syndrome] and after that it’s provided every 2 weeks after for an overall period of 2 years.
This consisted of a greatly pretreated client population with high-risk illness. Couple of clients had previous CD19 CAR T cells and an extremely little number of clients with previous CD 20 T-cell engagers. General high-risk illness and a greatly pretreated client population.
The drug is active. It revealed really high action rate and the CR [complete response] rate of 85%, consisting of in subsets with high-risk illness consisting of POD24 [disease progression within 24 months of frontline chemoimmunotherapy]And after that likewise appeared extremely active in the really little number of clients with previous treatment with CAR T cells and T-cell engagers.
The adverse effects are as anticipated, so CRS was among the most typical ones, however the majority of it was grade 1 with really couple of cases of grade 2. ICANS in follicular lymphoma, the threat of that was extremely low in the double step-up dosing accomplice. Appeared like a really active drug, a really appealing outcome, preliminary outcomes, and anticipated security profile for this class of drug.
Maddocks: Dr. Bond. Any extra ideas?
Bond: Yeah,
